Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year

Genomic Health Successfully Launched a Viral Educational Concept for Reaching People Touched by Breast Cancer Titled “Pass It On, Until Every Woman Knows”

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Indianapolis, IN (PRWEB) March 06, 2014

The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.

Genomic Health is a leading provider of genomic-based diagnostic tests that help improve the quality of cancer treatment decisions. Genomic Health was selected for the Marketer of the Year Award for their “Pass It On, Until Every Woman Knows” campaign, a viral, online educational campaign developed to create a new movement of awareness around a simple message―not every woman with early stage breast cancer needs chemotherapy. Their test, Oncotype DX®, helps newly diagnosed breast cancer patients and their physicians determine if she needs chemotherapy.

“Over the past decade, Genomic Health has redefined personalized medicine through the innovation of Oncotype DX, making genomics an indispensable part of breast cancer diagnosis and treatment,” said Kimberly J. Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. “It is our goal to reach everyone with messages about personalizing early-stage breast cancer treatment so that when a woman is diagnosed with breast cancer she will already know, or be told, about Oncotype DX. We remain steadfast in our mission to pass it on, until every woman knows!”

The “Pass It On, Until Every Woman Knows” campaign includes a consumer-based website, Facebook, YouTube and Twitter social media platforms to build awareness of the Oncotype DX test, and . has reached over 100 million people so far with an active Facebook community of more than 175,000 strong. Genomic Health continues to engage the breast cancer community with this campaign through the use of infographs and interactive campaigns.

For more information on attending the DxMA’s Global Marketing Summit and learning more about Genomic Health and their “Pass It On, Until Every Woman Knows” campaign, please click here.

About DxMA (Diagnostics Marketing Association)
The DxMA builds diagnostic industry leadership by providing knowledge and opportunities for professional development and the exchange of ideas. We serve marketing, regulatory compliance, business development and medical affairs professionals who have devoted their careers to the diagnostics, device and life science market segments. Members benefit from continued education and insight, networking with marketers from leading diagnostic companies and service providers, and the AACC seminar and DxMA Global Marketing Summit. For more information on the DxMA, visit the DxMA's website.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of September 30, 2013, more than 19,000 physicians in over 70 countries had ordered nearly 400,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, Genomic Health's website and follow the company on Twitter: @GenomicHealth.